Pennant Group (PNTG) is in focus after reporting second quarter 2026 earnings, updating full year revenue guidance to a range of $1.1711b to $1.1901b, and completing a senior living acquisition.

Pennant Group’s recent earnings beat and new Tucson senior living acquisition come after a strong run, with a 90 day share price return of 12.01% and a 1 year total shareholder return of 56.03%. This points to building momentum, supported by a 3 year total shareholder return above 200%.

If Pennant Group’s move has you thinking about where else growth might be emerging in healthcare, it could be worth checking a curated list of 40 healthcare AI stocks for fresh ideas.

Pennant Group now has a larger footprint, faster growth in reported revenue and strong recent returns on the stock. The real test for investors is whether that business strength is already fully reflected in today’s price.

Most Popular Narrative: 15.4% Undervalued

The most followed valuation narrative for Pennant Group places fair value at $46.33, above the last close of $39.18. This frames the current discount and sets up a detailed earnings and revenue story.

The accelerating demographic shift of an aging U.S. population is leading to rising demand for home health, hospice, and senior living services, as evidenced by Pennant's strong organic and acquisition-driven volume growth and robust occupancy/pricing trends in senior living. This ongoing demographic wave is described as expanding Pennant's addressable market and supporting long-term revenue growth in the narrative.

Want to understand why this narrative supports a higher value for Pennant Group? The model leans on faster earnings growth, improving margins and a richer future earnings multiple. Curious which assumptions really move the fair value line and how sensitive it is to revenue growth and profitability shifts? The full narrative lays out those moving parts in plain numbers.

Result: Fair Value of $46.33 (UNDERVALUED)

However, the Pennant Group narrative still leans on assumptions that could be challenged if CMS reimbursement cuts are more severe than expected or if labor costs remain elevated.

Another View: Pennant Group On Earnings Multiples

The earlier fair value narrative points to Pennant Group as undervalued, yet the current P/E of 42.3x tells a different story. That figure is well above the US Healthcare industry at 25.3x, the peer average at 29.8x, and a fair ratio estimate of 29.7x, which implies a higher valuation risk if sentiment shifts.

It leaves a clear question for investors. Is the earnings premium a sign that the market is already paying up for Pennant Group’s story, or could the share price move back toward that fair ratio over time, narrowing the gap?

Next Steps

If the mixed signals around Pennant Group leave you unsure, take a closer look at the numbers yourself and weigh the balance of concern and optimism. To see both sides set out clearly, review the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Pennant Group?

If Pennant Group has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with other stocks that fit different goals and risk levels.

• Target potential value opportunities by checking companies that currently screen as 53 high quality undervalued stocks and see which ones align with your approach.
• Prioritise resilience and sleep-better-at-night holdings through the 80 resilient stocks with low risk scores so you can focus on businesses with steadier profiles.
• Hunt for lesser-known prospects before the crowd notices by using the screener containing 19 high quality undiscovered gems and spot ideas you might otherwise miss.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.